phase i trial of arx517, an anti-psma adc, in mcrpc
Published 1 year ago • 372 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:06
psma adc in prostate cancer: phase i results
-
3:07
psma-trt, 225ac-j591 and 177lu-psma i&t in mcrpc
-
1:23
dr. petrylak on a phase ii trial of psma adc in taxane-treated mcrpc
-
0:50
psma adc for prostate cancer
-
1:05
dr. petrylak on psma adc for patients with mcrpc
-
8:23
results from a phase i study of amg 160
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
8:52
introduction lu177-psma prostate cancer
-
8:49
limitations of lutetium-177-psma & addressing treatment challenges
-
2:06:21
pcl #62 the current & future landscape - metastatic castrate resistant prostate cancer-oliver sartor
-
14:05
lutetium 177 psma - problems with the vision trial
-
1:15
updates in the treatment of castration-resistant prostate cancer
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
7:14
vision study
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
7:44
vision trial supports lupsma-targeting therapy for mcrpc | michael morris
-
6:56
oncological value of lutetium-177-psma therapy for mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
1:20
updates in psma radiopharmaceutical therapies for prostate cancer